😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingProCLAIM SALE

COVID shots should target variants with JN.1 lineage in 2024-25 campaign, US FDA advisers say

Published 06/05/2024, 09:22 AM
Updated 06/05/2024, 04:48 PM
© Reuters. FILE PHOTO: A nurse prepares a vaccine shot as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
PFE
-
NVAX
-
MRNA
-
BNTX
-

By Leroy Leo and Christy Santhosh

(Reuters) -Advisers to the U.S. Food and Drug Administration on Wednesday unanimously voted in favor of recommending that COVID-19 vaccines for 2024-25 should target a strain within the lineage of the JN.1 variant that has been dominant this year.

The 16 advisors did not vote on whether to favor the original JN.1 variant or one of its successors like the currently dominant KP.2 strain.

However, during their discussion they overwhelmingly recommended using the older JN.1 variant, particularly as it is the only strain for which Novavax (NASDAQ:NVAX) - one of the vaccine makers - said it would be able to target with its shot.

"We wanted to make sure that we gave people the option to potentially make a choice of a KP2 vaccine. We hear loud and clear from all of the members that they don't feel like that is necessary at this time," said Peter Marks, director of the FDA's Center for Biologics Evaluation & Research.

While the agency typically follows its advisers' recommendation when it makes its final decision, it is not obligated to do.

Shares of Novavax rose 18% on Wednesday, while Moderna (NASDAQ:MRNA) closed up 6.5%. Pfizer (NYSE:PFE) shares ended marginally higher.

COVID-19 vaccine makers earlier in the day said data from animals studies showed their 2024-25 shots targeting the JN.1 variant that was dominant earlier this year could neutralize newer subvariants such as KP.2 much better than the older shots.

Pfizer and partner BioNTech (NASDAQ:BNTX) said they will be ready to supply their updated vaccines immediately upon approval, while Moderna forecasts a timeline for August.

Pfizer and Moderna said they were ready to supply vaccines that target either JN.1 or KP.2 variants.

© Reuters. FILE PHOTO: A nurse prepares a vaccine shot as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo

Vaccines based on messenger RNA (mRNA) from Moderna and Pfizer/BioNTech can be developed more quickly. Pfizer had earlier said it could make the shots in 100 days.

Novavax, which makes a more traditional protein-based shot, said it expects to be ready for commercial delivery of its JN.1 vaccine in the United States in September.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.